CA2689664A1 - Cancer treatment combination therapy comprising vinflunine and trastuzumab - Google Patents
Cancer treatment combination therapy comprising vinflunine and trastuzumab Download PDFInfo
- Publication number
- CA2689664A1 CA2689664A1 CA2689664A CA2689664A CA2689664A1 CA 2689664 A1 CA2689664 A1 CA 2689664A1 CA 2689664 A CA2689664 A CA 2689664A CA 2689664 A CA2689664 A CA 2689664A CA 2689664 A1 CA2689664 A1 CA 2689664A1
- Authority
- CA
- Canada
- Prior art keywords
- vinflunine
- trastuzumab
- cancer
- weeks
- neoplasm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229960000922 vinflunine Drugs 0.000 title claims abstract description 44
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 29
- 229960000575 trastuzumab Drugs 0.000 title claims abstract description 29
- 201000011510 cancer Diseases 0.000 title claims abstract description 10
- NMDYYWFGPIMTKO-HBVLKOHWSA-N vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 title claims abstract 11
- 238000002560 therapeutic procedure Methods 0.000 title abstract description 3
- 238000011284 combination treatment Methods 0.000 title description 2
- 238000011282 treatment Methods 0.000 claims abstract description 22
- 206010055113 Breast cancer metastatic Diseases 0.000 claims description 13
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 13
- 241000124008 Mammalia Species 0.000 claims description 12
- 206010006187 Breast cancer Diseases 0.000 claims description 11
- 208000026310 Breast neoplasm Diseases 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 230000003442 weekly effect Effects 0.000 claims description 7
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 230000003321 amplification Effects 0.000 claims description 3
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 3
- 210000003679 cervix uteri Anatomy 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 201000003445 large cell neuroendocrine carcinoma Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 3
- 230000002018 overexpression Effects 0.000 claims description 3
- 208000029817 pulmonary adenocarcinoma in situ Diseases 0.000 claims description 3
- 208000000649 small cell carcinoma Diseases 0.000 claims description 3
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 229940034982 antineoplastic agent Drugs 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- NMDYYWFGPIMTKO-KLCPSUAYSA-N vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-KLCPSUAYSA-N 0.000 description 33
- 230000004044 response Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- YIHUEPHBPPAAHH-GBROPSEISA-N 194468-36-5 Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 YIHUEPHBPPAAHH-GBROPSEISA-N 0.000 description 1
- YUDPTGPSBJVHCN-DZQJYWQESA-N 4-methylumbelliferyl beta-D-galactoside Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YUDPTGPSBJVHCN-DZQJYWQESA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical group C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008228 bacteriostatic water for injection Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 231100000226 haematotoxicity Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000011227 neoadjuvant chemotherapy Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07290679.5 | 2007-05-31 | ||
| EP07290679A EP1997534A1 (en) | 2007-05-31 | 2007-05-31 | Cancer treatment combination therapy comprising vinflunine and trastuzumab |
| PCT/EP2008/056620 WO2008145697A1 (en) | 2007-05-31 | 2008-05-29 | Cancer treatment combination therapy comprising vinflunine and trastuzumab |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2689664A1 true CA2689664A1 (en) | 2008-12-04 |
Family
ID=38353425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2689664A Abandoned CA2689664A1 (en) | 2007-05-31 | 2008-05-29 | Cancer treatment combination therapy comprising vinflunine and trastuzumab |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20100196363A1 (enExample) |
| EP (2) | EP1997534A1 (enExample) |
| JP (1) | JP2010528091A (enExample) |
| KR (1) | KR20100017752A (enExample) |
| CN (1) | CN101687104A (enExample) |
| AR (1) | AR066778A1 (enExample) |
| AU (1) | AU2008257555A1 (enExample) |
| BR (1) | BRPI0812280A2 (enExample) |
| CA (1) | CA2689664A1 (enExample) |
| CL (1) | CL2008001589A1 (enExample) |
| IL (1) | IL202393A0 (enExample) |
| MX (1) | MX2009012874A (enExample) |
| NO (1) | NO20093536L (enExample) |
| RU (1) | RU2009146882A (enExample) |
| TN (1) | TN2009000490A1 (enExample) |
| TW (1) | TW200908976A (enExample) |
| WO (1) | WO2008145697A1 (enExample) |
| ZA (1) | ZA200908247B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| RU2737727C2 (ru) | 2013-04-16 | 2020-12-02 | Дженентек, Инк. | Варианты пертузумаба и их аналитическая характеристика |
| EP3481422A1 (en) * | 2016-07-06 | 2019-05-15 | Pierre Fabre Medicament | Vinflunine and pd1 and/or pdl1 inhibitor as pharmaceutical combination |
| TW202508629A (zh) | 2017-01-17 | 2025-03-01 | 美商建南德克公司 | 皮下her2抗體調配物 |
| KR20230144110A (ko) | 2017-03-02 | 2023-10-13 | 제넨테크, 인크. | Her2-양성 유방암 어쥬번트 치료 |
| JP2023532122A (ja) | 2020-06-29 | 2023-07-26 | ジェネンテック， インコーポレイテッド | ペルツズマブにトラスツズマブを加えた固定用量配合剤 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2707988B1 (fr) * | 1993-07-21 | 1995-10-13 | Pf Medicament | Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant. |
| FR2863891B1 (fr) * | 2003-12-23 | 2006-03-24 | Pf Medicament | Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation |
-
2007
- 2007-05-31 EP EP07290679A patent/EP1997534A1/en not_active Ceased
-
2008
- 2008-05-05 US US12/602,127 patent/US20100196363A1/en not_active Abandoned
- 2008-05-12 TW TW097117418A patent/TW200908976A/zh unknown
- 2008-05-29 MX MX2009012874A patent/MX2009012874A/es not_active Application Discontinuation
- 2008-05-29 EP EP08760211A patent/EP2164573A1/en not_active Withdrawn
- 2008-05-29 WO PCT/EP2008/056620 patent/WO2008145697A1/en not_active Ceased
- 2008-05-29 RU RU2009146882/15A patent/RU2009146882A/ru not_active Application Discontinuation
- 2008-05-29 CN CN200880017406A patent/CN101687104A/zh active Pending
- 2008-05-29 AU AU2008257555A patent/AU2008257555A1/en not_active Abandoned
- 2008-05-29 CA CA2689664A patent/CA2689664A1/en not_active Abandoned
- 2008-05-29 JP JP2010509824A patent/JP2010528091A/ja not_active Withdrawn
- 2008-05-29 KR KR1020097025793A patent/KR20100017752A/ko not_active Withdrawn
- 2008-05-29 BR BRPI0812280-6A2A patent/BRPI0812280A2/pt not_active IP Right Cessation
- 2008-05-30 AR ARP080102281A patent/AR066778A1/es not_active Application Discontinuation
- 2008-05-30 CL CL2008001589A patent/CL2008001589A1/es unknown
-
2009
- 2009-11-23 ZA ZA200908247A patent/ZA200908247B/xx unknown
- 2009-11-23 TN TNP2009000490A patent/TN2009000490A1/fr unknown
- 2009-11-29 IL IL202393A patent/IL202393A0/en unknown
- 2009-12-16 NO NO20093536A patent/NO20093536L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0812280A2 (pt) | 2014-11-18 |
| KR20100017752A (ko) | 2010-02-16 |
| AR066778A1 (es) | 2009-09-09 |
| JP2010528091A (ja) | 2010-08-19 |
| CN101687104A (zh) | 2010-03-31 |
| EP2164573A1 (en) | 2010-03-24 |
| IL202393A0 (en) | 2010-06-30 |
| US20100196363A1 (en) | 2010-08-05 |
| WO2008145697A1 (en) | 2008-12-04 |
| TW200908976A (en) | 2009-03-01 |
| RU2009146882A (ru) | 2011-07-10 |
| EP1997534A1 (en) | 2008-12-03 |
| AU2008257555A1 (en) | 2008-12-04 |
| TN2009000490A1 (en) | 2011-03-31 |
| CL2008001589A1 (es) | 2009-03-06 |
| MX2009012874A (es) | 2010-03-31 |
| NO20093536L (no) | 2009-12-16 |
| ZA200908247B (en) | 2010-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100196363A1 (en) | Cancer treatment combination therapy comprising vinflunine and trastuzumab | |
| KR102446673B1 (ko) | 암 치료를 위한 약물의 제조에 있어서 항-pd-1 항체 및 vegfr 억제제의 조합의 용도 | |
| AU2016309002A1 (en) | Combination therapy using liposomal irinotecan and a PARP inhibitor for cancer treatment | |
| EP3042669B1 (en) | Antitumor agent and antitumor effect enhancer | |
| JP2018506550A (ja) | 癌治療のための併用療法 | |
| CA3215047A1 (en) | Therapeutic compositions and methods for treating tumors | |
| Akinleye et al. | Novel agents for advanced pancreatic cancer | |
| US20230201303A1 (en) | Methods for treating pancreatic cancer and other solid tumors | |
| US20120196828A1 (en) | Sensitization of cancer cells to treatment | |
| Smith et al. | Pertuzumab for the treatment of patients with previously untreated HER2-positive metastatic breast cancer | |
| CN104755497A (zh) | 结合抗癌治疗剂的双特异性scfv轭合物的剂量和给药 | |
| Tanaka et al. | Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience | |
| KR20240130081A (ko) | 항-trop-2 항체-약물 접합체와 추가 치료제의 병용 사용 | |
| AU2022381992A1 (en) | Lurbinectedin and atezolizumab combinations | |
| KR20250133269A (ko) | 나노입자 및 방사성 의약품을 사용한 조합 요법 | |
| HK1139345A (en) | Cancer treatment combination therapy comprising vinflunine and trastuzumab | |
| EP4659741A1 (en) | Use of paclitaxel cationic liposome in treating tumors | |
| Dragnev et al. | A dose escalation trial of biweekly docetaxel and gemcitabine with filgrastim or pegfilgrastim for the treatment of patients with advanced solid tumors | |
| Patnaik et al. | ENZ-2208, a novel anticancer agent, in patients with advanced malignancies: a phase 1 dose-escalation study | |
| TW202527951A (zh) | 用於治療乳腺癌的方法 | |
| CN107126563B (zh) | 含低剂量阻断vegf信号通路的抗体的组合物及其用途 | |
| Kelly et al. | 404 POSTER A phase I study of oral administration of the histone deacetylase (HDAC) inhibitor belinostat in patients (pts) with advanced solid tumors | |
| Modi et al. | Development of Inhibitors of HER2 With Taxanes | |
| Modi et al. | New Directions in Breast Cancer Therapy | |
| HK1257249B (en) | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20130529 |